MONROE, La., Feb. 28, 2019 – Furthering its dedication to helping protect the internet from malicious actors, CenturyLink, Inc. (NYSE:CTL) is sharing intelligence on the Necurs botnet uncovered by its new threat research and operations division, Black Lotus Labs.
The mission of Black Lotus Labs is to leverage CenturyLink’s network visibility to help protect customers and keep the internet clean. Among the ways Black Lotus Labs does this is by tracking and disrupting botnets like Necurs, a prolific and globally dispersed spam and malware distribution botnet which has recently demonstrated a hiding technique to both avoid detection and quietly amass more bots.
To view the multimedia release go to:
https://www.multivu.com/players/English/8238355-centurylink-black-lotus-labs/
The Leukemia & Lymphoma Society (LLS) today announced it has committed $28.6 million in new research investment to advance the most promising blood cancer science at leading academic and medical institutions around the world, including Dana-Farber Cancer Institute, Weill Cornell Medical College and MD Anderson Cancer Center. As LLS leads the charge to find cures for cancer patients, this new funding, along with ongoing investment in LLS’s aggressive research agenda, brings LLS’s total commitment to blood cancer research to more than $1 billion. The investment has led to the development of nearly every therapy currently used to treat the blood cancers.
Along with these new research grants, LLS remains committed to collaborating with biotechnology companies through its innovative Therapy Acceleration Program® (TAP), a model pioneered by LLS in the cancer arena in recognition that traditional research approaches weren’t yielding treatments and cures fast enough for patients. LLS commits approximately $13 million a year to its TAP initiatives. As part of the 24 current such collaborations, LLS recently initiated new investments with Kite Pharma and OncoPep.
To view the multimedia release go to:
http://www.multivu.com/players/English/7554852-lls-cancer-research-funding/
CVS Health, the nation’s largest pharmacy innovation company, today launched an in-store fundraising campaign at CVS Pharmacy locations nationwide to benefit the American Lung Association’s LUNG FORCE initiative which aims to make lung cancer, the leading cancer killer of women in the United States, a public health priority.
Now through June 11, customers can donate $1, $3 or more at the register at 7,900 CVS Pharmacy locations and online at www.cvs.com/lung (all proceeds will support the initiative). CVS Health is the national presenting sponsor of LUNG FORCE, which is focused on raising awareness about lung cancer in women, and increasing research funding to save lives.
To view the multimedia release go to:
http://www.multivu.com/players/English/7817251-cvs-health-lung-force-fundraiser/
Popular tradition gives vinegar many healthful benefits, both through topical and internal use: it is antiseptic, antioxidant, purifying, soothing, protective, and toning.
This new interest motivated hair colouring pioneer Christophe Robin to study the cosmetic properties linked to vinegar, and research formulas inspired by traditional recipes to create a product that meets the current needs of both men and women.
To view the Multimedia News Release, go to http://www.multivu.com/players/uk/7560651-christophe-robins-botanical-vinegars/
Today, the Crohn’s & Colitis Foundation of America (CCFA) unveiled its newest fundraising and endurance initiative, spin4 crohn’s & colitis cures, an indoor cycling event that will raise funds for research, awareness, and patient services. The inaugural event will take place on December 5th at local studios and fitness centers in New York, Los Angeles, and Chicago as part of Crohn’s and Colitis Awareness Week.
“We’re eager to create a movement by launching spin4 crohn’s & colitis curesacross the country on December 5,” said Craig Comins, vice president of CCFA’s Team Challenge program. “It’s about motivating advocates to contribute to the IBD community and take research to the next level. We welcome all ages and athletic abilities to join us with one united voice to spin4 cures.”
Individuals form teams of up to four people per bike and participate in a two-hour indoor cycling relay. Alternatively, solo riders can take on the entire two-hours themselves. No matter the size of the team, each bike has a $1,000 fundraising commitment for CCFA. Professional instructors will lead teams to high-energy music offering a lively workout experience. The event is capped off with a cocktail hour to reward participants for their efforts in the stationary bike relay and fundraising success.
To view the multimedia news release visit
http://www.multivu.com/players/English/7512651-ccfa-spin4-crohns-colitis-cures/
The Celiac Disease Center at Columbia University, the premier center for celiac disease research and treatment, unveiled the I Didn’t Know video campaign, offering an inside look at the serious impact of celiac disease on patients at the 13th Anniversary gala on November 13th in New York City. The series chronicles the lives of several patients experiencing a wide range of debilitating symptoms associated with undiagnosed celiac disease, including an inability to walk, developmental delays, multiple miscarriages and infertility.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/7322351-celiac-disease-center-at-columbia-university-public-service-announcements-and-gala/
The St. Jude Promesa y Esperanza® (Promise and Hope), an initiative by St. Jude Children’s Research Hospital® and Univision Radio, the leading radio network serving Hispanic America, partner to increase awareness for national fundraiser against childhood cancer. As part of this partnership, Univision Radio will broadcast special programming on February 10 and 11 asking listeners to become Angeles de Esperanza (Angels of Hope) by making a donation of $20 per month, to find cures and save children.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/65476-univision-radio-st-jude-children-s-research-hospital-national-fundraiser
Anyone who has seen the blockbuster movies The Thomas Crown Affair or Bullitt will want to read The Pursuit of Happiness, a new novel by the same writer, Alan Trustman. The highest paid screenwriter in Hollywood at one time, Trustman now turns his pen to fiction, which reads and moves with the same crime thriller speed as his movies.
From the opening chapter we are rocketed into the world of a Boston bad boy who is recruited to work for the government.
“All of the material in The Pursuit of Happiness is true,” says Trustman. “Not a lot of people know that Boston was the contract killing capitol of the country throughout the 1940s – 1970s. Maybe later. I did a lot of research on the Boston gang wars.”
Media Contact: For a review copy of Silver Dollar or to arrange an interview with Alan Trustman, contact Scott Lorenz of Westwind Communications Book Marketing at scottlorenz@westwindcos.com or by phone at 734-667-2090 http://www.book-marketing-expert.com Thriller
Researchers at global public health organization NSF International, Harvard Medical School, the United States Department of Defense and the National Institute for Public Health and the Environment in the Netherlands (RIVM) recently identified four unapproved, DMAA-like stimulants in six over-the-counter weight-loss and pre-workout products currently available online. The research was published in the peer-reviewed journal Clinical Toxicology.
The potentially harmful compounds – including banned stimulants 1,3-DMAA and 1,3-DMBA as well as octodrine and a newly identified DMAA analog – were not listed as ingredients in the products and may have been disguised as “2-aminoisoheptane” or extract of Aconitum kusnezoffii. These stimulants may cause adverse cardiac events, hemorrhagic strokes or sudden death, especially if taken prior to strenuous exercise or combined with caffeine. Extreme heat and dehydration may also increase the health risks.
To view the multimedia release go to:
https://www.multivu.com/players/English/8216951-nsf-international-banned-stimulants-2-aminoisoheptane/
LivaNova PLC (NASDAQ:LIVN; LSE: LIVN) (“LivaNova” or the “Company”), a market-leading medical technology and innovation company, today recognizes that more than one million people in the United States with drug-resistant epilepsy continue to be treated unsuccessfully with drugs, despite the proven effectiveness of non-drug treatment options. LivaNova’s VNS Therapy®, for example, is a medical device treatment specifically designed for people with drug-resistant epilepsy that is already used by more than 85,000 people around the world.
One in three people with epilepsy has the type that is not well controlled with drugs, called drug-resistant epilepsy. For those people, prescribing more medicine is usually not the most effective option. In fact, research shows that if you haven’t found seizure freedom after your first two drugs, there is a 95 percent chance that no drug or combination of drugs will result in seizure freedom.
“Despite what we know about drug-resistant epilepsy, the majority of people affected by this condition will continue to be prescribed additional medications instead of being evaluated for surgery or seen in a specialized epilepsy facility,” said Jason Richey, president of LivaNova’s U.S. Region and general manager of the Neuromodulation Business Franchise. “This treatment gap means over one million individuals in the U.S. with undertreated epilepsy remain at risk for dangerous side effects of continued seizures, including injury, depression, memory issues and death.”
To view the multimedia release go to:
http://www.multivu.com/players/English/7966451-livanova-vns-therapy-epilepsy/
http://www.garrettrobins.net/dogsandcars
The age old question has been answered. Through extensive research,
hard work and determination Garrett Robins accomplished the impossible.
Since the first known domesticated dog people have always wondered what
type of car do dogs really prefer. Human beings prefer different types
of cars where Mr. Robbins was able to determine that dogs only like
luxury cars. For more information see www.garrettrobins.net/dogsandcars
Sesame Workshop, the nonprofit educational organization that produces Sesame Street, and IBM (NYSE:IBM) today announced a collaboration to use IBM Watson’s cognitive computing technology and Sesame’s early childhood expertise to help advance preschool education around the world.
As part of a three-year agreement, Sesame Workshop and IBM will collaborate to develop educational platforms and products that will be designed to adapt to the learning preferences and aptitude levels of individual preschoolers. Research shows that a significant extent of brain development occurs in the first five years of a child’s life1, making this window critical for learning and development.
To view the multimedia release go to:
http://www.multivu.com/players/English/7724251-sesame-workshop-ibm-watson-early-childhood-education/